文献速递胃肠外科围术期管理与 ERAS

普芦卡必利对择期结直肠手术后肠道功能恢复时间的影响:随机临床试验

Effect of prucalopride to improve time to gut function recovery following elective colorectal surgery: randomized clinical trial.
PubMed 文献 · Br J Surg · 2022-01-01

这项多中心双盲安慰剂对照随机试验纳入148例择期结直肠切除患者,普芦卡必利2mg组与安慰剂组的主要终点GI-2恢复时间无差异(3.5天 vs 4天,P=0.124),但普芦卡必利缩短了排便时间(3天 vs 4天,P=0.027),在腹腔镜手术亚组中改善了GI-2时间(3天 vs 4天,P=0.012)。

要点

  • 普芦卡必利未改善择期结直肠手术后整体肠道功能恢复时间。
  • 普芦卡必利缩短排便时间,但未缩短耐受饮食时间和住院时间。
  • 腹腔镜手术患者中普芦卡必利可能改善GI-2恢复时间。

核心结论

  • 普芦卡必利未改善择期结直肠手术后肠道功能的总体恢复时间。

研究设计与样本

  • 多中心、双盲、平行、安慰剂对照随机试验,纳入148例择期结直肠切除患者,按1:1随机分配至普芦卡必利2mg组或安慰剂组。
  • 研究药物术前2小时给予,术后每日给予至多6天;排除炎症性肠病及计划行回肠造口者,允许结肠造口。

主要发现

  • 普芦卡必利组与安慰剂组的中位GI-2时间无差异:3.5(四分位距2-5)天 vs 4(3-5)天,P=0.124。
  • 普芦卡必利组中位排便时间短于安慰剂组:3天 vs 4天,P=0.027。
  • 两组中位耐受饮食时间无差异:2天 vs 2天,P=0.669;中位住院时间无差异:4天 vs 4天,P=0.929。
  • 腹腔镜手术患者(125例,84.5%)中,普芦卡必利组中位GI-2时间短于安慰剂组:3(2-4)天 vs 4(3-5)天,P=0.012。
  • 两组PPOI发生率、并发症及不良事件发生率相似。

临床怎么用

  • 普芦卡必利不推荐用于常规改善择期结直肠手术后整体肠道功能恢复。
  • 腹腔镜结直肠手术患者可考虑使用普芦卡必利以改善肠道功能恢复时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delayed return to gut function and prolonged postoperative ileus (PPOI) delay recovery after colorectal surgery. Prucalopride is a selective serotonin-4-receptor agonist that may improve gut motility. METHODS: This was a multicentre, double-blind, parallel, placebo-controlled randomized trial of 2 mg prucalopride versus placebo in patients undergoing elective colorectal resection. Patients with inflammatory bowel disease and planned ileostomy formation were excluded, but colostomy formation was allowed. The study medication was given 2 h before surgery and daily for up to 6 days after operation. The aim was to determine whether prucalopride improved return of gut function and reduced the incidence of PPOI. The primary endpoint was time to passage of stool and tolerance of diet (GI-2). Participants were allocated in a 1 : 1 ratio, in blocks of 10. Randomization was computer-generated. All study personnel, medical staff, and patients were blinded. RESULTS: This study was completed between October 2017 and May 2020 at two tertiary hospitals in New Zealand. A total of 148 patients were randomized, 74 per arm. Demographic data were similar in the two groups. There was no difference in median time to GI-2 between prucalopride and placebo groups: 3.5 (i.q.r. 2-5) versus 4 (3-5) days respectively (P = 0.124). Prucalopride improved the median time to passage of stool (3 versus 4 days; P = 0.027) but not time to tolerance of diet (2 versus 2 days; P = 0.669) or median duration of hospital stay (4 versus 4 days; P = 0.929). In patients who underwent laparoscopic surgery (125, 84.5 per cent), prucalopride improved median time to GI-2: 3 (2-4) days versus 4 (3-5) days for placebo (P = 0.012). The rate of PPOI, complications, and adverse events was similar in the two groups. CONCLUSION: Prucalopride did not improve time to overall recovery of gut function after elective colorectal surgery. Registration number: NCT02947269 (http://www.clinicaltrials.gov).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Milne T, Liu C, O'Grady G, et al. Effect of prucalopride to improve time to gut function recovery following elective colorectal surgery: randomized clinical trial. Br J Surg. 2022. PMID: 35639621. doi:10.1093/bjs/znac121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。